Conestoga Capital Advisors LLC boosted its position in Omnicell Inc. (NASDAQ:OMCL) by 2.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,510,059 shares of the company’s stock after buying an additional 36,325 shares during the period. Omnicell comprises approximately 4.0% of Conestoga Capital Advisors LLC’s investment portfolio, making the stock its largest position. Conestoga Capital Advisors LLC owned about 4.18% of Omnicell worth $57,835,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its position in Omnicell by 77.2% in the second quarter. Victory Capital Management Inc. now owns 3,069 shares of the company’s stock worth $105,000 after buying an additional 1,337 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Omnicell by 605.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,374 shares of the company’s stock worth $150,000 after buying an additional 3,754 shares in the last quarter. PineBridge Investments L.P. raised its position in Omnicell by 4.0% in the second quarter. PineBridge Investments L.P. now owns 4,555 shares of the company’s stock worth $156,000 after buying an additional 177 shares in the last quarter. Teacher Retirement System of Texas raised its position in Omnicell by 13.8% in the second quarter. Teacher Retirement System of Texas now owns 4,957 shares of the company’s stock worth $170,000 after buying an additional 600 shares in the last quarter. Finally, Stephens Inc. AR raised its position in Omnicell by 20.5% in the second quarter. Stephens Inc. AR now owns 5,160 shares of the company’s stock worth $177,000 after buying an additional 878 shares in the last quarter. 94.56% of the stock is owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Omnicell Inc. (NASDAQ:OMCL) traded up 3.25% on Monday, reaching $34.90. 212,190 shares of the company traded hands. The firm has a market cap of $1.27 billion, a P/E ratio of 160.09 and a beta of 0.65. Omnicell Inc. has a 52-week low of $25.06 and a 52-week high of $40.50. The stock has a 50-day moving average price of $34.46 and a 200-day moving average price of $35.22.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, October 27th. The company reported $0.40 EPS for the quarter, missing analysts’ consensus estimates of $0.41 by $0.01. Omnicell had a net margin of 1.24% and a return on equity of 10.74%. The firm earned $179.40 million during the quarter, compared to the consensus estimate of $179.75 million. During the same period last year, the business earned $0.36 EPS. The business’s revenue was up 43.3% on a year-over-year basis. Analysts anticipate that Omnicell Inc. will post $1.55 earnings per share for the current fiscal year.

A number of research analysts have recently commented on the stock. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $46.00 price objective on shares of Omnicell in a research report on Tuesday, September 13th. TheStreet lowered shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Friday, November 11th. FBR & Co upped their price objective on shares of Omnicell from $40.00 to $41.00 and gave the company an “outperform” rating in a research report on Friday, July 29th. Zacks Investment Research lowered shares of Omnicell from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 3rd. Finally, Sidoti lowered shares of Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 price objective for the company. in a research report on Thursday, September 8th. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Omnicell has an average rating of “Buy” and an average target price of $39.43.

In other news, VP Jorge R. Taborga sold 2,068 shares of Omnicell stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $33.66, for a total value of $69,608.88. Following the completion of the transaction, the vice president now owns 47,223 shares of the company’s stock, valued at approximately $1,589,526.18. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Gary S. Petersmeyer sold 2,000 shares of Omnicell stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $39.02, for a total transaction of $78,040.00. Following the completion of the transaction, the director now directly owns 19,987 shares of the company’s stock, valued at approximately $779,892.74. The disclosure for this sale can be found here. 3.75% of the stock is currently owned by insiders.

Omnicell Company Profile

Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.

5 Day Chart for NASDAQ:OMCL

Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.